Antibiotice
Antibiotice S.A., a prominent player in the pharmaceutical industry, is headquartered in Iaşi, Romania. Established in 1955, the company has evolved into a leading manufacturer of generic antibiotics and other essential medications, serving both domestic and international markets. With a strong focus on research and development, Antibiotice has achieved significant milestones, including the production of innovative formulations and a robust portfolio of over 200 products. The company’s core offerings include injectable antibiotics, oral medications, and topical treatments, distinguished by their high quality and efficacy. Antibiotice is recognised for its commitment to sustainability and compliance with international standards, positioning itself as a trusted partner in healthcare. With a solid market presence in Europe and beyond, Antibiotice continues to contribute to global health through its dedication to pharmaceutical excellence.
DitchCarbon Score
How does Antibiotice's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antibiotice's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Antibiotice's reported carbon emissions
In 2024, Antibiotice S.A., headquartered in Romania, reported total carbon emissions of approximately 94,954,410 kg CO2e. This figure includes Scope 1 emissions of about 9,495,410 kg CO2e, primarily from stationary combustion, which accounted for approximately 8,620,690 kg CO2e. Scope 2 emissions were reported at about 3,589,130 kg CO2e (market-based), while Scope 3 emissions were significantly higher at approximately 73,014,390 kg CO2e, with the largest contributions from purchased goods and services (about 57,818,330 kg CO2e) and capital goods (approximately 11,076,080 kg CO2e). Antibiotice has set ambitious climate commitments, aiming for a 46% reduction in greenhouse gas emissions for its operations (Scope 1 and 2) by 2030, using 2019 as the baseline year. This commitment reflects the company's proactive approach to addressing climate change within the pharmaceutical sector. The company is currently classified as "Committed" to near-term targets, although it has not yet established a net-zero target. Antibiotice's emissions data is independently reported and not cascaded from any parent organisation, ensuring transparency in its climate reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 10,417,990 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,296,330 | - | - | - | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Antibiotice is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
